GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Return-on-Tangible-Asset

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Return-on-Tangible-Asset : -451.20% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Brainstorm Cell Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-22.31 Mil. Brainstorm Cell Therapeutics's average total tangible assets for the quarter that ended in Dec. 2023 was $4.95 Mil. Therefore, Brainstorm Cell Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -451.20%.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

BCLI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -271.62   Med: -116.63   Max: -35.78
Current: -268.96

During the past 13 years, Brainstorm Cell Therapeutics's highest Return-on-Tangible-Asset was -35.78%. The lowest was -271.62%. And the median was -116.63%.

BCLI's Return-on-Tangible-Asset is ranked worse than
93.69% of 1554 companies
in the Biotechnology industry
Industry Median: -40.005 vs BCLI: -268.96

Brainstorm Cell Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Return-on-Tangible-Asset Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -261.83 -110.09 -60.74 -128.69 -271.62

Brainstorm Cell Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -184.95 -247.94 -313.03 -85.82 -451.20

Competitive Comparison of Brainstorm Cell Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Return-on-Tangible-Asset falls into.



Brainstorm Cell Therapeutics Return-on-Tangible-Asset Calculation

Brainstorm Cell Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-17.192/( (8.451+4.208)/ 2 )
=-17.192/6.3295
=-271.62 %

Brainstorm Cell Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-22.312/( (5.682+4.208)/ 2 )
=-22.312/4.945
=-451.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Brainstorm Cell Therapeutics  (NAS:BCLI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Brainstorm Cell Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Executives
Stacy Lindborg officer: EVP, Head Global Clin Research C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor director BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor officer: Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits officer: Chief Executive Officer 110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun officer: EVP and COO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd. other: Member of 10% owner group MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi director 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel director 188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya officer: Chief Commercial Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah officer: EVP, CFO and Treasurer C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel director 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Headlines

From GuruFocus